Waystar Considers Strategic Options Amid Market Challenges

Waystar, a prominent healthcare software company, is reportedly evaluating various strategic options, including the possibility of a sale. This development comes just two years after the company went public on the New York Stock Exchange. According to seven sources familiar with the matter, investment bank Evercore is advising Waystar during this exploratory phase.

Market Value Decline Spurs Strategic Review

Waystar's market value has suffered a 24% decline this year, settling at approximately $4.8 billion. This downturn is part of a broader selloff affecting the software sector, prompting the company to reassess its strategic direction. While the auction process is still in its early stages, it could serve as a litmus test for investor interest in software businesses.

The company, which operates out of Lehi, Utah, and Louisville, Kentucky, has emphasized its identity as a healthcare software provider. By focusing on automating administrative tasks, Waystar aims to achieve higher valuations typically associated with technology firms, as opposed to traditional healthcare services that rely more on manual labor.

Investor Sentiment and AI Concerns

Initially, Waystar's strategy garnered investor enthusiasm, with shares climbing from $20 to a peak of $45 in 2025. However, concerns over potential disruptions from advancements in artificial intelligence have since put pressure on the stock. A report by Morgan Stanley analysts in July highlighted these challenges for software companies.

Waystar was created in 2017 through the merger of healthcare revenue management companies Zirmed and Navicure. Its largest stakeholders include EQT, the Canada Pension Plan Investment Board (CPPIB), and Bain Capital. EQT currently holds a 13% stake, while CPPIB and BlackRock Institutional Trust Company own 10% and 8%, respectively.

Responses and Next Steps

When approached for comments, Waystar, EQT, and BlackRock declined to provide any statements, while CPPIB did not immediately respond. Evercore also did not comment on the matter.

As Waystar navigates this period of uncertainty, the outcome of its strategic review remains to be seen. Whether the company will proceed with a sale or pursue alternative strategies will depend on the evolving market conditions and investor interest.